Abstract
Colin Chu will outline their current work in developing novel imaging-based biomarkers to manage patients with blinding eye diseases. This spans adaptive optics and OCT-based imaging of immune cells in clinical trials and mouse models, alongside new spatial proteomic technologies to better define the actual biological correlates of retinal imaging features.
 

Biosketch
Colin Chu is a Wellcome Trust Fellow, a research group leader at UCL Institute of Ophthalmology and a Consultant Ophthalmologist at Moorfields Eye Hospital, London. He undertook his PhD at UCL, was an NIHR Clinical Lecturer at the University of Bristol and a post doctoral Fulbright Scholar at NIAID at National Institutes of Health in the USA. His research employs cutting- edge imaging technologies to improve our understanding of retinal disorders and the care of patients with inflammatory eye diseases such as Uveitis.
 

www.colinchulab.com